MED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Medifast Inc (MED) is not a strong buy at this moment for a beginner investor with a long-term strategy. The company's financial performance has significantly deteriorated, and there are no strong positive catalysts or trading signals to justify immediate investment. While insider buying is a positive indicator, the lack of growth in coach count and poor financial trends outweigh this. A hold is recommended until clearer signs of recovery or growth emerge.
The MACD is positive and expanding, suggesting a bullish momentum. However, the RSI is in the neutral zone at 73.596, and moving averages are converging, indicating no strong directional trend. The stock is trading near its pivot point of 10.495 with resistance at 10.917 and support at 10.073.
Insider buying has increased significantly by 3472.36% over the last month, indicating confidence from internal stakeholders.
Analysts have lowered price targets, citing concerns about growth in coach count. No recent news or significant external catalysts.
In Q4 2025, revenue dropped to $75.1M (-36.90% YoY), net income fell to -$18.1M (-2362.05% YoY), and EPS dropped to -1.65 (-2457.14% YoY). Gross margin also declined to 69.43% (-6.34% YoY), reflecting poor financial health.
Stephens lowered the price target from $15 to $12 and maintained an Equal Weight rating, citing concerns about the company's ability to return to growth in coach count.
